HC Wainwright Has Strong Forecast for KROS FY2025 Earnings

Keros Therapeutics, Inc. (NASDAQ:KROS) – Stock analysts at HC Wainwright lifted their FY2025 earnings per share estimates for shares of Keros Therapeutics in a research note issued on Thursday, November 6th. HC Wainwright analyst A. Maldonado now forecasts that the company will post earnings of $2.68 per share for the year, up from their previous estimate of ($1.20). HC Wainwright has a “Buy” rating and a $20.00 price objective on the stock. The consensus estimate for Keros Therapeutics’ current full-year earnings is ($4.74) per share. HC Wainwright also issued estimates for Keros Therapeutics’ Q4 2025 earnings at ($0.16) EPS, Q1 2026 earnings at ($0.45) EPS, Q2 2026 earnings at ($0.47) EPS, Q3 2026 earnings at ($0.48) EPS, Q4 2026 earnings at ($0.48) EPS, FY2026 earnings at ($4.01) EPS, FY2027 earnings at ($4.71) EPS, FY2028 earnings at ($3.42) EPS and FY2029 earnings at ($2.68) EPS.

Several other research firms also recently weighed in on KROS. Weiss Ratings restated a “sell (d)” rating on shares of Keros Therapeutics in a report on Wednesday, October 8th. Wells Fargo & Company lowered their target price on shares of Keros Therapeutics from $26.00 to $23.00 and set an “overweight” rating on the stock in a report on Tuesday. Wedbush raised their price target on shares of Keros Therapeutics from $15.00 to $16.00 and gave the company a “neutral” rating in a research report on Thursday, November 6th. Finally, Zacks Research raised Keros Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Friday, November 7th. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, seven have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $29.78.

Keros Therapeutics Trading Down 0.8%

Shares of NASDAQ KROS opened at $16.90 on Monday. Keros Therapeutics has a 1-year low of $9.12 and a 1-year high of $72.37. The firm has a market capitalization of $514.94 million, a P/E ratio of 10.97, a P/E/G ratio of 0.38 and a beta of 1.12. The firm’s 50-day moving average price is $15.56 and its 200-day moving average price is $14.67.

Keros Therapeutics (NASDAQ:KROS) last issued its quarterly earnings results on Wednesday, November 5th. The company reported ($0.18) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.11) by $0.93. The firm had revenue of $14.26 million during the quarter, compared to the consensus estimate of $4.22 million. Keros Therapeutics had a return on equity of 9.51% and a net margin of 26.12%.The business’s revenue was up 3585.6% compared to the same quarter last year. During the same period last year, the business posted ($1.41) EPS.

Institutional Trading of Keros Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the company. ADAR1 Capital Management LLC boosted its holdings in Keros Therapeutics by 6,294.5% in the 1st quarter. ADAR1 Capital Management LLC now owns 1,486,461 shares of the company’s stock valued at $15,147,000 after purchasing an additional 1,463,215 shares during the period. Federated Hermes Inc. raised its position in shares of Keros Therapeutics by 882.3% in the first quarter. Federated Hermes Inc. now owns 1,224,139 shares of the company’s stock worth $12,474,000 after buying an additional 1,099,519 shares in the last quarter. Vanguard Group Inc. boosted its stake in Keros Therapeutics by 31.1% during the first quarter. Vanguard Group Inc. now owns 2,566,321 shares of the company’s stock valued at $26,151,000 after buying an additional 609,212 shares during the period. DRW Securities LLC bought a new stake in Keros Therapeutics during the first quarter valued at $4,737,000. Finally, Canada Pension Plan Investment Board purchased a new position in Keros Therapeutics during the second quarter worth about $4,251,000. 71.56% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, major shareholder Pontifax Management 4 G.P. (20 sold 4,787,331 shares of the stock in a transaction dated Wednesday, October 15th. The shares were sold at an average price of $17.75, for a total value of $84,975,125.25. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, major shareholder Adar1 Capital Management, Llc sold 5,389,264 shares of the firm’s stock in a transaction that occurred on Wednesday, October 15th. The shares were sold at an average price of $17.75, for a total transaction of $95,659,436.00. The disclosure for this sale is available in the SEC filing. Insiders own 22.90% of the company’s stock.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.